Ganirelix

Indications

Ganirelix is used for: Ovarian stimulation, Assisted reproduction

Adult Dose

Subcutaneous Female Infertility 250 mcg SC qDay during mid-to-late follicular phase after initiating follicle-stimulating hormone on day 2 and 3 of the cycle, continue therapy until day of hCG administration Hepatic impairment: Moderate to severe: Contraindicated.

Child Dose

Renal Dose

Renal impairment: Moderate to severe: Contraindicated.

Administration

Contra Indications

Hypersensitivity, pregnancy, lactation, moderate to severe renal or hepatic impairment.

Precautions

Women with active allergic conditions or a history of allergies. Lactation: Excretion unknown; not recommended

Pregnancy-Lactation

Interactions

May require dose adjustment of exogenous gonadotropins when concomitantly used during controlled ovarian hyperstimulation.

Adverse Effects

Side effects of Ganirelix : 1-10% Abdominal pain (1%),Headache (3%),Injection site recation (1%),Nausea (1%),Ovarian hyperstimulation syndrome (2%),Vaginal bleeding (2%),Pelvic pain (5%) <1% Anaphylactoid reactions

Mechanism of Action

Ganirelix is a gonadorelin (gonadotrophin-releasing hormone) antagonist. It competitively blocks the gonadotropin-release hormone receptors on the pituitary gonadotroph and transduction pathway. This suppresses gonadotropin secretion and luteinising hormone secretion thus preventing ovulation until the follicles are of adequate size.